Sinovac's serum-free rabies vaccine matches licensed shot on a simplified 4-dose schedule
A 2,000-participant Phase III trial found 100% seroconversion by day 14 across a serum-free vaccine's 5-dose and two 4-dose regimens, each meeting noninferiority against a licensed comparator.
Executive Summary
- A randomized, double-blind trial compared a serum-free rabies vaccine given on a standard five-visit schedule and two simplified four-visit schedules against a licensed rabies vaccine, all following simulated post-exposure prophylaxis.
- Every study group, including both simplified schedules, reached complete seroconversion by two weeks and held that response through six weeks, meeting the trial's prespecified bar for matching the licensed comparator.
- Protective antibody levels persisted through six months across all groups, and adverse reactions were mild and similar between the test and control arms, with no vaccine-related serious events.
- The results support a four-dose post-exposure schedule as a viable alternative to the standard five-dose regimen, with the potential to cut the number of clinic visits patients need to complete prophylaxis.
The stake
Rabies is close to universally fatal once symptoms appear, and post-exposure prophylaxis remains the only intervention that reliably prevents disease after a bite or scratch from an infected animal. The standard regimen requires five vaccine doses delivered over four weeks, a schedule that depends on patients returning to a clinic multiple times to complete the course. A vaccine that works as well on fewer visits addresses a real barrier to completing prophylaxis, particularly where access to repeat clinic visits is limited. The trial tested whether a serum-free formulation, which avoids animal-derived components used in some legacy vaccines, could preserve full protection while cutting one dose from the schedule. ImmunogenicityImmunogenicity and safety of serum-free rabies vaccine for human use with simulated post-exposure schedules: A randomized, double-blind, active-controlled phase III clinical trial.Jul 15, 2026
How it was done
The trial randomized 2,000 healthy participants aged 10 to 60 in a 1:1:1:1 ratio to four groups: a serum-free vaccine given on the standard five-dose Essen schedule (days 0, 3, 7, 14, 28), the same vaccine given on one of two simplified four-dose schedules (days 0, 3, 7, 14 or days 0, 3, 7, 28), or a licensed rabies vaccine on the standard five-dose schedule as the active control. The trial was double-blind. Its primary endpoints were seroconversion rates and geometric mean antibody concentrations on day 14, and seroconversion rates on day 42, measured in participants who started with low baseline rabies antibody levels. Secondary endpoints tracked day-28 antibody response, seropositive rates at 3 and 6 months, and safety through 6 months. ImmunogenicityImmunogenicity and safety of serum-free rabies vaccine for human use with simulated post-exposure schedules: A randomized, double-blind, active-controlled phase III clinical trial.Jul 15, 2026
The result
Among susceptible participants, seroconversion reached 100% on days 14, 28, and 42 in all four groups. Day-14 antibody concentrations were 34.71 and 36.36 IU/mL in the two four-dose groups, 33.17 IU/mL in the five-dose test group, and 37.38 IU/mL in the licensed-vaccine control group. All three serum-free vaccine regimens, including both simplified four-dose schedules, met the trial's prespecified noninferiority criteria against the licensed comparator on day-14 and day-42 seroconversion and day-14 antibody concentration. ImmunogenicityImmunogenicity and safety of serum-free rabies vaccine for human use with simulated post-exposure schedules: A randomized, double-blind, active-controlled phase III clinical trial.Jul 15, 2026
Durability and tolerability
Seropositive rates held at 100% at three months and above 97% at six months across all serum-free vaccine groups, indicating the antibody response persisted well beyond the dosing period. Safety profiles were comparable across all four groups. Most adverse reactions were Grade 1 in severity, and no vaccine-related serious adverse events were reported in any group. Matching tolerability across the simplified and standard schedules removes a safety trade-off as a reason to prefer the longer regimen. ImmunogenicityImmunogenicity and safety of serum-free rabies vaccine for human use with simulated post-exposure schedules: A randomized, double-blind, active-controlled phase III clinical trial.Jul 15, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.